GEn1E Lifesciences YC 申请
GEn1E Lifesciences 在 Summer 2019 批次的 Y Combinator 中作为一家 Healthcare 公司进行过。以下是：公司做什么、谁创立了它，以及其 YC 申请，按照真实 YC 表格逐题重建。
- YC 批次
- Summer 2019
- 行业
- HealthcareTherapeutics
- 状态
- Active
- 已发布
- 2022
创始人
Ritu LalFounder
GEn1E Lifesciences 做什么
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
GEn1E Lifesciences 的 YC 申请，重建版
Y Combinator 申请
GEn1E Lifesciences，Summer 2019 期。来自公开数据的真实申请问题解答。
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
GEn1E Lifesciences
AI platform accelerating therapies for rare diseases
We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.
We live in Palo Alto, CA, and the company is based here.
Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.
21 更多回答 在完整申请中
Founders, Progress, Idea, Equity, Curious, Batch Preference 包含在完整版中。创建免费账户即可在 YC Insights 中打开，紧邻每个其他 YC 批次。
常见问题解答
这是 GEn1E Lifesciences 的真实 YC 申请吗？
不是。Y Combinator 对提交的申请保密。这是重建版：使用 GEn1E Lifesciences 的公开数据（发布笔记、创始人背景、产品描述）回答真实的 YC 表格问题。它展示了像 GEn1E Lifesciences 这样的公司会如何向 YC 自我介绍，而不是他们提交的文本。
GEn1E Lifesciences 是哪个 YC 批次的？
GEn1E Lifesciences 是 Y Combinator Summer 2019 批次的成员。
谁创立了 GEn1E Lifesciences？
GEn1E Lifesciences 由 Ritu Lal 创立。
GEn1E Lifesciences 做什么？
AI platform accelerating therapies for rare & inflammatory diseases.
如何阅读完整的重建申请？
创建免费的 Round Funded 账户。YC Insights 中包含 GEn1E Lifesciences 的完整 26 个问题的版本，以及其他所有 YC 批次的公司信息。
更多 YC 初创公司，例如 GEn1E Lifesciences
